ADVA wins two MEF 3.0 Proof of Concept Awards
10.3.2021 21:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that it has jointly won two awards at the MEF 3.0 Proof of Concept (PoC) Showcase. The honors recognize innovation and leadership with emerging services and technologies involving AI, SD-WAN, service automation and more. The Judge’s Choice Award for the best overall PoC was presented to a multi-vendor solution using ADVA’s Ensemble NFV suite to deliver personalized and automatically generated live video content over optimized network slices. Leveraging AI video technology and uCPE hosting SD-WAN, the demo showed how service providers can meet demand for unique immersive experiences of events such as live sports. ADVA also won the Market Game Changer Award, recognizing the largest potential impact on the service provider market. This was presented for its collaboration on a PoC using ADVA Ensemble software to enable multi-edge cloud services. This technology will be key to empowering enterprises to provide low-latency, high-throughput applications such as smart factories and industrial IoT.
“Our award-winning demo, Revolutionizing Live Events, illustrates how cable network operators can deliver exciting new services in an entirely original way. We’ve shown that it’s now possible to offer a unique, differentiated experience of live events that puts audiences at the heart of the action. Sports or music fans could soon be selecting their own viewing angles and receiving coverage that automatically zooms and tracks in real time. And for service providers, this points to a simple and cost-effective way of enabling high-volume, high-margin entertainment services,” said James Buchanan, GM, Edge Cloud, ADVA. “We’ve shown that utilizing uCPE and network slicing over enterprise networks can transform the way video content is produced and distributed. This cloud-based, virtualized approach opens the door to new levels of flexibility and automation for video services. What’s more, it highlights the potential of uCPE as a platform for innovation ready to unleash an array of new applications and business models.”
Featuring ADVA’s Ensemble suite of NFV software, the Revolutionizing Live Events PoC highlighted new opportunities for service providers to meet the growing expectations of sports and entertainment audiences. Driven by compute-based AI/ML, MEF-defined network slicing and lightweight uCPE running SD-WAN, the demo showed how network resources can be utilized to provide automated, highly personalized video content.
ADVA’s other award-winning PoC was the Orchestrated Multi-Edge Clouds demo. For this, the Ensemble NFV suite was deployed to manage and orchestrate SD-WAN, IoT, 5G networking and other edge-cloud technologies, seamlessly enabling the distribution of smart manufacturing resources between on-premises and network edge cloud environments. This demo paves the way for enterprises to purchase mission-critical applications and services flexibly and on demand.
“Our multi-edge cloud MEF 3.0 PoC is a key step in helping businesses to improve operational efficiency as they continue to digitize and automate their processes. It shows how service providers can accelerate adoption of multi-edge cloud services through the orchestration of applications and connectivity on open edge compute platforms. Winning the Market Game Changer Award underlines the impact on enterprises of being able to instantly purchase applications such as IoT, SD-WAN and wireless network access from a single managed service provider and have them automatically deployed across multiple cloud platforms,” commented Mike Heffner, VP, product line management, Edge Cloud, ADVA. “Using our Ensemble NFV software, this PoC proves that it’s now possible to relieve businesses of the responsibility and burden of multi-vendor system integration. This creates a major opportunity for service providers. They can offer on-demand, managed edge services and connectivity on open edge compute platforms that can be deployed in multiple locations. And, using advanced analytics, they can select the best edge location for IoT applications to meet SLAs.”
More information about the Revolutionizing Live Events PoC is available here: https://adva.li/mef-poc-live-events.
Further details on the Orchestrated Multi-Edge Clouds demo can be viewed here: https://adva.li/mef-poc-multi-edge-clouds.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005482/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Industrial Decarbonization: Calderion, WenCo and Terravent Invest in Graforce to Scale Plasma Pyrolysis Globally25.2.2026 09:07:00 EET | Press release
The investor consortium comprising the Paris-based Next Generation Fuels Industrial & Technological fund Calderion (Audacia), alongside infrastructure developer Terravent and WenCo Family Office, announces the closing of a strategic double-digit million-euro financing round for Berlin-based Graforce GmbH. The investment is dedicated to the industrial scale-up of Graforce’s proprietary plasma pyrolysis technology, addressing the growing global demand for cost-efficient low-carbon hydrogen, syngas, and carbon removal solutions that are compatible with existing industrial infrastructures. Disruptive alternative to conventional processes Graforce’s technology aims at replacing CO₂-intensive legacy routes such as steam reforming and classical gasification. By applying plasma to methane, biogas, flare gas, and landfill gas, the process converts these streams into their valuable molecular components instead of emitting them. The result is a high-efficiency production of clean hydrogen and syn
Mevion Medical Systems Announces CE Marking of the MEVION S250-FIT™ Proton Therapy System, Expanding Global Access to Compact Proton Therapy25.2.2026 09:00:00 EET | Press release
Mevion Medical Systems, the global leader in compact proton therapy, today announced that the MEVION S250-FIT Proton Therapy System has successfully completed the conformity assessment process and has received CE Marking under Regulation (EU) 2017/745 (EU MDR). This regulatory milestone enables the marketing, sale, and clinical use of the MEVION S250-FIT system throughout the European Union, building on the system’s existing U.S. FDA 510(k) clearance granted in September 2025. The MEVION S250-FIT is the first and only proton therapy system designed to fit into a standard radiation therapy vault. By enabling cancer centers to use their existing infrastructure, the MEVION S250-FIT dramatically reduces the cost, complexity, and timeline traditionally associated with proton therapy adoption. This opens a new pathway for hospitals and cancer centers across Europe to bring advanced proton treatment to their patients. “With both FDA clearance and CE Marking now in hand, the MEVION S250-FIT is
Bureau Veritas: Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 08:30:00 EET | Press release
Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2024, › Free Cash Flow of EUR 824.2 million, up 3.9% organically and up 2.6% at constant currency, and cash conversion of 107%2, › Adjusted net
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 08:00:00 EET | Press release
Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat in a mouse model in Sandhoff disease, a form of GM2 gangliosidosis with no approved treatments—alongside healthy control subjects. The research assessed how the drug’s exposure relates to its effects in the brain, demonstrating a significant increase in both survival (22%; 26 days) and assessments of movement and behavior at 16 weeks versus un
Galderma Announces Triple Approval of New State-of-the-Art Restylane ® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 08:00:00 EET | Press release
Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-art syringe for use with its NASHA® lidocaine range of Restylane products in multiple facial indications including the cheeks, nose, chin, jawline, tear troughs, nasolabial folds, marionette lines, as well as in the hands.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224651688/en/ The syringe features a next-generation ergonomic design that enhances precision and control; includes an optimized syringe-needle connection with the new Terumo K-Pack Enhance™ needle; and offers a premium color-coded packaging and syringe design to support easy range navigation for practitioners.4-7, 9,10 It sets a new standard in Injectable Aesthetic devices and demonstrates Galderma’s unwavering commitment to driving innovation to meet the needs of both practitioners and patients. “Developing this new syringe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom